These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

647 related items for PubMed ID: 15880796

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Mutation specific therapy in CF.
    Kerem E.
    Paediatr Respir Rev; 2006; 7 Suppl 1():S166-9. PubMed ID: 16798551
    [Abstract] [Full Text] [Related]

  • 3. Gentamicin-induced correction of CFTR function in patients with cystic fibrosis and CFTR stop mutations.
    Wilschanski M, Yahav Y, Yaacov Y, Blau H, Bentur L, Rivlin J, Aviram M, Bdolah-Abram T, Bebok Z, Shushi L, Kerem B, Kerem E.
    N Engl J Med; 2003 Oct 09; 349(15):1433-41. PubMed ID: 14534336
    [Abstract] [Full Text] [Related]

  • 4. Nonsense-mediated mRNA decay affects nonsense transcript levels and governs response of cystic fibrosis patients to gentamicin.
    Linde L, Boelz S, Nissim-Rafinia M, Oren YS, Wilschanski M, Yaacov Y, Virgilis D, Neu-Yilik G, Kulozik AE, Kerem E, Kerem B.
    J Clin Invest; 2007 Mar 09; 117(3):683-92. PubMed ID: 17290305
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Pharmacologic therapy for stop mutations: how much CFTR activity is enough?
    Kerem E.
    Curr Opin Pulm Med; 2004 Nov 09; 10(6):547-52. PubMed ID: 15510065
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Correctors promote folding of the CFTR in the endoplasmic reticulum.
    Loo TW, Bartlett MC, Clarke DM.
    Biochem J; 2008 Jul 01; 413(1):29-36. PubMed ID: 18361776
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Future pharmacological treatment of cystic fibrosis.
    Zeitlin PL.
    Respiration; 2000 Jul 01; 67(4):351-7. PubMed ID: 10940786
    [Abstract] [Full Text] [Related]

  • 11. Direct interaction of a small-molecule modulator with G551D-CFTR, a cystic fibrosis-causing mutation associated with severe disease.
    Pasyk S, Li C, Ramjeesingh M, Bear CE.
    Biochem J; 2009 Feb 15; 418(1):185-90. PubMed ID: 18945216
    [Abstract] [Full Text] [Related]

  • 12. Specific rescue of cystic fibrosis transmembrane conductance regulator processing mutants using pharmacological chaperones.
    Wang Y, Bartlett MC, Loo TW, Clarke DM.
    Mol Pharmacol; 2006 Jul 15; 70(1):297-302. PubMed ID: 16624886
    [Abstract] [Full Text] [Related]

  • 13. Modulation of deltaF508 cystic fibrosis transmembrane regulator trafficking and function with 4-phenylbutyrate and flavonoids.
    Lim M, McKenzie K, Floyd AD, Kwon E, Zeitlin PL.
    Am J Respir Cell Mol Biol; 2004 Sep 15; 31(3):351-7. PubMed ID: 15191910
    [Abstract] [Full Text] [Related]

  • 14. A cluster of cystic fibrosis mutations in the first nucleotide-binding fold of the cystic fibrosis conductance regulator protein.
    Cutting GR, Kasch LM, Rosenstein BJ, Zielenski J, Tsui LC, Antonarakis SE, Kazazian HH.
    Nature; 1990 Jul 26; 346(6282):366-9. PubMed ID: 1695717
    [Abstract] [Full Text] [Related]

  • 15. The role of common single-nucleotide polymorphisms on exon 9 and exon 12 skipping in nonmutated CFTR alleles.
    Steiner B, Truninger K, Sanz J, Schaller A, Gallati S.
    Hum Mutat; 2004 Aug 26; 24(2):120-9. PubMed ID: 15241793
    [Abstract] [Full Text] [Related]

  • 16. The human DnaJ homologue (Hdj)-1/heat-shock protein (Hsp) 40 co-chaperone is required for the in vivo stabilization of the cystic fibrosis transmembrane conductance regulator by Hsp70.
    Farinha CM, Nogueira P, Mendes F, Penque D, Amaral MD.
    Biochem J; 2002 Sep 15; 366(Pt 3):797-806. PubMed ID: 12069690
    [Abstract] [Full Text] [Related]

  • 17. [Cystic fibrosis: molecular update and clinical implications].
    Orozco L, Chávez M, Saldaña Y, Velázquez R, Carnevale A, González-del Angel A, Jiménez S.
    Rev Invest Clin; 2006 Sep 15; 58(2):139-52. PubMed ID: 16827266
    [Abstract] [Full Text] [Related]

  • 18. Insights into the mechanisms underlying CFTR channel activity, the molecular basis for cystic fibrosis and strategies for therapy.
    Kim Chiaw P, Eckford PD, Bear CE.
    Essays Biochem; 2011 Sep 07; 50(1):233-48. PubMed ID: 21967060
    [Abstract] [Full Text] [Related]

  • 19. Cystic fibrosis patients with the 3272-26A-->G mutation have mild disease, leaky alternative mRNA splicing, and CFTR protein at the cell membrane.
    Beck S, Penque D, Garcia S, Gomes A, Farinha C, Mata L, Gulbenkian S, Gil-Ferreira K, Duarte A, Pacheco P, Barreto C, Lopes B, Cavaco J, Lavinha J, Amaral MD.
    Hum Mutat; 1999 Sep 07; 14(2):133-44. PubMed ID: 10425036
    [Abstract] [Full Text] [Related]

  • 20. A novel exon in the cystic fibrosis transmembrane conductance regulator gene activated by the nonsense mutation E92X in airway epithelial cells of patients with cystic fibrosis.
    Will K, Dörk T, Stuhrmann M, Meitinger T, Bertele-Harms R, Tümmler B, Schmidtke J.
    J Clin Invest; 1994 Apr 07; 93(4):1852-9. PubMed ID: 7512993
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 33.